Please use this identifier to cite or link to this item:
Type
PreprintCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- BA - IGM - Preprint [97]
- BSB - Preprint [18]
- MS - Preprint [4]
Metadata
Show full item record
EFFECTIVENESS OF CORONAVAC, CHADOX1, BNT162B2 AND AD26.COV2.S AMONG INDIVIDUALS WITH PRIOR SARS-COV-2 INFECTION IN BRAZIL
COVID-19
CoronaVac
Estudos de casos e controles
Controle de doenças transmissíveis
CoronaVac
ChAdOx1
BNT162b2 and Ad26.COV2.S
Test-negative study
Case-control study
Previous infections
Todos os dados foram pseudo-anônimos com um identificador único comum fornecido pelo Ministério da Saúde do Brasil. O protocolo de pesquisa foi aprovado pela Comissão Nacional de Ética em Pesquisa (CONEP) (número de aprovação 4.921.308).
Author
Affilliation
Abstract
Background: COVID-19 vaccines have proven highly effective among SARS-CoV-2 naive individuals, but their effectiveness in preventing symptomatic infection and severe outcomes among individuals with prior infection is less clear. Methods: Utilizing national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, we performed a case-control study using a test-negative design to assess the effectiveness of four vaccines (CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2) among individuals with laboratory-confirmed prior SARS-CoV-2 infection. We matched RTPCR positive, symptomatic COVID-19 cases with RT-PCR-negative controls presenting with symptomatic illnesses, restricting both groups to tests performed at least 90 days after an initial infection. We used multivariable conditional logistic regression to compare the odds of test positivity, and the odds of hospitalization or death due to COVID-19, according to vaccination status and time since first or second dose of vaccines. Findings: Among individuals with prior SARS-CoV-2 infection, vaccine effectiveness against symptomatic infection ≥ 14 days from vaccine series completion was 39.4% (95% CI 36.1-42.6) for CoronaVac, 56.0% (95% CI 51.4-60.2) for ChAdOx1, 44.0% (95% CI 31.5-54.2) for Ad26.COV2.S, and 64.8% (95% CI 54.9-72.4) for BNT162b2. For the two-dose vaccine series (CoronaVac, ChAdOx1, and BNT162b2), effectiveness against symptomatic infection was significantly greater after the second dose compared with the first dose. Effectiveness against hospitalization or death ≥ 14 days from vaccine series completion was 81.3% (95% CI 75.3-85.8) for CoronaVac, 89.9% (95% CI 83.5-93.8) for ChAdOx1, 57.7% (95% CI -2.6-82.5) for Ad26.COV2.S, and 89.7% (95% CI 54.3-97.7) for BNT162b2. Interpretation. All four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. Provision of a full vaccine series to individuals following recovery from COVID-19 may reduce morbidity and mortality.
Keywords in Portuguese
CoronavírusCOVID-19
CoronaVac
Estudos de casos e controles
Controle de doenças transmissíveis
Keywords
COVID-19CoronaVac
ChAdOx1
BNT162b2 and Ad26.COV2.S
Test-negative study
Case-control study
Previous infections
Publisher
Yale University
Citation
CERQUEIRA-SILVA, Thiago et al. Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil. The BMJ, p. 1-30, 27 Dec. 2021.DOI
10.1101/2021.12.21.21268058Notes
Dados da pesquisa estão no anexo do artigo.Todos os dados foram pseudo-anônimos com um identificador único comum fornecido pelo Ministério da Saúde do Brasil. O protocolo de pesquisa foi aprovado pela Comissão Nacional de Ética em Pesquisa (CONEP) (número de aprovação 4.921.308).
Share